The MAPK pathway regulates intrinsic resistance to BET inhibitors in colorectal cancer.
The bromodomain and extra-terminal domain (BET) family proteins are epigenetic readers for acetylated histone marks. Emerging BET bromodomain inhibitors have exhibited antineoplastic activities in a wide range of human cancers through suppression of oncogenic transcription factors, including MYC. However, the preclinical activities of BET inhibitors in advanced solid cancers are moderate at best. To improve BET-targeted therapy, we interrogated mechanisms mediating resistance to BET inhibitor...Expand abstract
- Publication status:
- Peer review status:
- Peer reviewed
(Accepted manuscript, pdf, 2.4MB)
- Publisher copy:
- Copyright holder:
- American Association for Cancer Research
- Copyright date:
- Copyright © 2016, American Association for Cancer Research.
If you are the owner of this record, you can report an update to it here: Report update to this record